Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report.
De Divitiis C, von Arx C, Carbone R, Tatangelo F, Di Girolamo E, Romano GM, Ottaiano A, de Lutio di Castelguidone E, Iaffaioli RV, Tafuto S. De Divitiis C, et al. Among authors: von arx c. Onco Targets Ther. 2015 Mar 31;8:669-75. doi: 10.2147/OTT.S71025. eCollection 2015. Onco Targets Ther. 2015. PMID: 25878507 Free PMC article.
Everolimus and pancreatic neuroendocrine tumors (PNETs): Activity, resistance and how to overcome it.
Capozzi M, Caterina I, De Divitiis C, von Arx C, Maiolino P, Tatangelo F, Cavalcanti E, Di Girolamo E, Iaffaioli RV, Scala S, Tafuto S; ENETS Center of Excellence Multidisciplinary Group for Neuroendocrine Tumors in Naples (Italy). Capozzi M, et al. Among authors: von arx c. Int J Surg. 2015 Sep;21 Suppl 1:S89-94. doi: 10.1016/j.ijsu.2015.06.064. Epub 2015 Jun 27. Int J Surg. 2015. PMID: 26123382 Free article. Review.
Antiangiogenic Therapy in Pancreatic Neuroendocrine Tumors.
Capozzi M, VON Arx C, DE Divitiis C, Ottaiano A, Tatangelo F, Romano GM, Tafuto S; (On behalf of ENETS Center of Excellence Multidisciplinary Group for Neuroendocrine Tumors in Naples, Italy). Capozzi M, et al. Among authors: von arx c. Anticancer Res. 2016 Oct;36(10):5025-5030. doi: 10.21873/anticanres.11071. Anticancer Res. 2016. PMID: 27798861 Review.
A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial.
von Arx C, Della Vittoria Scarpati G, Cannella L, Clemente O, Marretta AL, Bracigliano A, Picozzi F, Iervolino D, Granata V, Modica R, Bianco A, Mocerino C, Di Mauro A, Pizzolorusso A, Di Sarno A, Ottaiano A, Tafuto S; ENETs Center of Excellence in Naples, Italy and with the endorsement of the Italian Association for Neuroendocrine Tumor IT.A.NET. von Arx C, et al. ESMO Open. 2024 May;9(5):103003. doi: 10.1016/j.esmoop.2024.103003. Epub 2024 Apr 13. ESMO Open. 2024. PMID: 38615472 Free PMC article. Clinical Trial.
30 results